Stockscreener 앱 받기
77.69
0.17%
0.13
시장 영업 전:
77.34
-0.35
-0.45%
Astrazeneca PLC 주식(AZN)의 최신 뉴스
3,345 Shares in AstraZeneca PLC $AZN Acquired by Ashton Thomas Private Wealth LLC - MarketBeat
Acadian Asset Management LLC Has $6.03 Million Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial - Benzinga
AstraZeneca’s Fasenra RESOLUTE Failure Highlights The Limits Of Biologicals In COPD - insights.citeline.com
AstraZeneca's (AZN) Fasenra COPD Trial Misses Key Endpoint - GuruFocus
AstraZeneca fails to meet main goal in lung disease trial (AZN) - Seeking Alpha
AstraZeneca (AZN) Advances Saphnelo Injectable in Key Phase 3 Tr - GuruFocus
AstraZeneca posts late-stage trial win for injectable Saphnelo in SLE - Seeking Alpha
AstraZeneca reports positive Phase III results for Saphnelo in lupus trial By Investing.com - Investing.com South Africa
Investment crisis: AstraZeneca halts $271m UK expansion - BioXconomy
Advancing Cancer Research Brings New Hope for Patients Worldwide - Benzinga
Assessing AstraZeneca Shares After Investment Pause in Britain and Recent Price Slide - Yahoo Finance
AstraZeneca reports positive Phase III results for Saphnelo in lupus trial - Investing.com
AstraZeneca (AZN) Reports Positive Phase III TULIP-SC Trial Resu - GuruFocus
AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease - Stocktwits
AstraZeneca Says Phase 3 Trial of Fasenra in COPD Fails to Meet Primary Endpoint - MarketScreener
Canandaigua National Bank & Trust Co. Has $1.38 Million Stake in AstraZeneca PLC $AZN - MarketBeat
Howe & Rusling Inc. Sells 35,353 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca says Fasenra misses main goal in COPD trial By Investing.com - Investing.com Nigeria
AstraZeneca Asthma Drug Fails COPD Study for a Second Time - Bloomberg.com
AstraZeneca lupus drug Saphnelo shows promise in self-injection trial - Proactive Investors
AstraZeneca's asthma drug fails 'smoker's lung' study - Reuters
AstraZeneca says Saphnelo met primary endpoint in Tulip-SC - MarketScreener
AstraZeneca's Systemic Lupus Erythematosus Medicine Meets Primary Endpoint in Late-stage Trial - MarketScreener
AstraZeneca's Fasenra Fails to Meet Primary Endpoint in Pulmonary Disease Trial - MarketScreener
AstraZeneca's asthma drug fails main goal of COPD study - MarketScreener
AstraZeneca : Saphnelo met primary endpoint in TULIP-SC - MarketScreener
AstraZeneca : Update on RESOLUTE Phase III trial - MarketScreener
Retail Trends: Should I hold or sell AstraZeneca PLC Depositary Receipt now2025 Analyst Calls & Fast Gaining Stock Reports - خودرو بانک
Value Recap: Should I hold or sell AstraZeneca PLC Depositary Receipt nowJuly 2025 PostEarnings & Stepwise Trade Execution Plans - خودرو بانک
Bull Bear: Can AstraZeneca PLC Depositary Receipt expand into new marketsWeekly Trade Report & Expert Curated Trade Setup Alerts - خودرو بانک
AstraZeneca Sales, Profit Outshine Estimates on Cancer Drugs - MSN
Aug Sentiment: Is AstraZeneca PLC Depositary Receipt vulnerable to short sellersLayoff News & Smart Money Movement Alerts - خودرو بانک
Wesbanco Bank Inc. Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Canandaigua National Trust Co of Florida Has $784,000 Stake in AstraZeneca PLC $AZN - MarketBeat
Ascent Group LLC Acquires New Holdings in AstraZeneca PLC $AZN - MarketBeat
Goldman Sachs raises AstraZeneca stock price target on HPP drug potential - Investing.com UK
Focus Partners Wealth Has $5.85 Million Stake in AstraZeneca PLC $AZN - MarketBeat
Q4 EPS Estimates for AstraZeneca Increased by Zacks Research - MarketBeat
Momentum Shift: Why is AstraZeneca PLC Depositary Receipt stock going upWeekly Trading Summary & Weekly Watchlist of Top Performers - خودرو بانک
Short Covering: Is AstraZeneca PLC Depositary Receipt gaining market share2025 Historical Comparison & High Return Stock Watch Alerts - خودرو بانک
AstraZeneca drags FTSE 100 lower ahead of key central bank decisions - MarketScreener
AstraZeneca PLC (AZN) Receives Tagrisso Boost in Lung Cancer Trials - Yahoo Finance
AstraZeneca halts £200m research investment in Cambridge - Yahoo Finance
AstraZeneca shares down 3% after rating cut, UK investment pause - Reuters
AstraZeneca, strong sterling drag FTSE 100 lower ahead of key central bank decisions - MarketScreener
Trade Report: Is HTLM stock undervalued right nowJuly 2025 Chart Watch & Free Safe Capital Growth Stock Tips - خودرو بانک
AstraZeneca falls 3% as £200m Cambridge expansion put on hold By Investing.com - Investing.com Nigeria
AstraZeneca falls 3% as £200m Cambridge expansion put on hold - Investing.com
AstraZeneca Pauses $271 Million Cambridge Project - MarketScreener
365,000 Shares in AstraZeneca PLC $AZN Acquired by Strs Ohio - MarketBeat
Integrity Alliance LLC. Makes New $440,000 Investment in AstraZeneca PLC $AZN - MarketBeat
Exome Asset Management LLC Invests $2.39 Million in AstraZeneca PLC $AZN - MarketBeat
Growth Value: Whats the outlook for AstraZeneca PLC Depositary Receipts sectorWeekly Trade Analysis & Community Consensus Trade Alerts - خودرو بانک
AstraZeneca pauses £200 million investment in new research facility - MarketScreener
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site - MarketScreener
AstraZeneca PLC $AZN Shares Bought by Fred Alger Management LLC - MarketBeat
Voya Investment Management LLC Acquires 443,795 Shares of AstraZeneca PLC $AZN - MarketBeat
Q2 EPS Estimates for AstraZeneca Increased by Zacks Research - MarketBeat
자본화:
|
볼륨(24시간):